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Background: Glycogen synthase kinase-3β (GSK3β) expression and activity are upregulated in pancreatic cancer
tissues. In our previous study, we found that stromal cell-derived factor-1/ chemokine receptor C-X-C motif chemokine
receptor 4 (SDF-1α/CXCR4) upregulated matrix metalloproteinase 2 (MMP-2) and promoted invasion in PANC1 and
SW-1990 pancreatic cancer cells by activating p38 mitogen-activated protein kinase (p38 MAPK). Additionally, inhibition
of GSK3β reduced MMP-2 secretion.
Methods: To investigate the molecular mechanism of GSK3β in pancreatic cancer tissues, we created stable PANC1
cells up-regulation of GSK3β by transfecting GSK3β overexpression plasmid, and down-regulation of GSK3β using two
different types of RNA interference.
Results: Western blotting showed that overexpression of GSK3β up-regulated CXCR4 and MMP-2 expression;
suppression of GSK3β down-regulated CXCR4 and MMP-2 protein expression. Up-regulation of MMP2 induced
by overexpression of GSK3β was blocked by inhibition of CXCR4. Overexpression of GSK3β promoted PANC1
cell invasion, and down-regulation of GSK3β suppressed PANC1 cell invasion in the transwell invasion assays.
However, inhibition of CXCR4 using shRNA attenuated the ability of GSK3β to promote PANC1 cell invasion.
Conclusions: This study demonstrated that GSK3β promotes PANC1 cell invasion via the CXCR4/MMP-2
pathway.
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Pancreatic cancer is one of the most aggressive human
cancers worldwide. Despite the introduction of improved
and/or combined treatments such as surgery, chemother-
apy and radiation therapy, the prognosis of patients with
pancreatic cancer remains poor. Novel, effective thera-
peutic strategies are urgently required to improve the
prognosis of patients with this malignancy. Improvements
to chemotherapy strategies require the development of
novel target-directed therapies. Therefore, further studies
are needed to identify novel molecular therapeutic targets
which determine the sensitivity of pancreatic cells to che-
motherapeutic agents and ionizing radiation [1].* Correspondence: fengliupan@126.com
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creativecommons.org/publicdomain/zero/1.0/The serine/threonine kinase glycogen synthase kinase-3
(GSK3) was originally identified as a regulator of glycogen
synthesis [2, 3]. GSK3β phosphorylates and inactivates the
enzyme glycogen synthase. However, GSK3β is also in-
volved in diverse cellular processes such as cell prolifera-
tion, apoptosis, invasion and inflammation. Altered
GSK3β expression is associated with numerous patho-
logical processes, including type 2 diabetes, Alzheimer’s
disease, and cancer [4–7]. Recent studies suggested that
GSK3β can promote the invasion of pancreatic, lung,
breast and liver cancer cells, and inhibition of GSK3β in-
duces apoptosis [8–10]. These results have led researchers
to propose GSK3β as a potential therapeutic target in can-
cer. Recent studies have also indicated that GSK3β pro-
motes the proliferation and invasion of pancreatic cancer
cells. Inhibition of GSK3β triggered an apoptotic response
in pancreatic cancer cells via a JNK-dependent mechanism
[11], and attenuated cell survival and proliferation and in-
duced apoptosis in pancreatic cancer cell lines [5].le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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tor 4 (CXCR4) and its natural ligand stromal cell-
derived factor-1 (CXCL12, SDF-1) play a role in a
variety of physiological and pathological processes, in-
cluding cell proliferation, migration and invasion [12].
Matrix metalloproteinase 2 (MMP-2) promotes the in-
vasion of a variety of cancer cells, including pancre-
atic cancer cells [13]. SDF-1/CXCR4 and MMP-2 are
overexpressed in pancreatic cancer tissues, and have
been found to act as prognostic markers in various
types of cancer, including pancreatic cancer. SDF-1/
CXCR4 are thought to promote pancreatic cancer cell
invasion by upregulating the expression and activity
of MMP-2 [14–17]. Inhibition of GSK3β enhanced
Mesenchymal stromal cells (MSCs) migration by in-
creasing expression of CXCR4 [18]. SDF1/CXCR4 had
effect on resident c-kit(+) CSPCs by increasing
GSK3β activity [19]. Silencing of GSK3β decreased
CXCL12 expression (the ligand of CXCR4) [20].Fig. 1 Overexpression of GSK3β upregulates CXCR4 and MMP-2 prote
were transfected with either the GSK3β overexpressing plasmid pcDN
clones were selected. Total cell lysates were isolated and subjected t
antibodies; α-tubulin was used as a loading control. a Western blot a
vector control and GSK3β-overexpressing PANC1 cells. c Western blot
control, vector control and GSK3β-overexpressing SW-1990 cells. b an
and c based on gray-scale analysis. Results are expressed as mean ± SHere, we investigated the relationship between GSK3β
and CXCR4/MMP-2 in pancreatic cancer cells, in order to
further characterize the cellular and molecular mecha-
nisms involved in pancreatic cancer.Results
Overexpression of GSK3β upregulates CXCR4 and MMP-2
To elucidate the effect of GSK3β on the expression of
CXCR4 and MMP-2 in pancreatic cancer cells, we
overexpresses GSK3β in PANC1 and SW-1990 cells.
Fig. 1a show that, compared to control PANC1 cells
and vector control cells, GSK3β expression increases
by about 2.3-fold in the stable cell clone; this clone is
used as a cellular model of GSK3β overexpression in
the remainder of the study.
We determine the expression of CXCR4 and MMP-
2 in PANC1 cells overexpressing GSK3β using West-
ern blotting. Overexpression of GSK3β upregulatesin expression. PANC1 and SW-1990 human pancreatic cancer cells
A3.1A(-)-myc-GSK3β or empty vector as a control, and stable cell
o Western blotting using anti-human GSK3β, CXCR4 and MMP-2
nalysis of GSK3β, CXCR4 and MMP-2 protein expression in control,
analysis of GSK3β, CXCR4 and MMP-2 protein expression in
d d Quantification of GSK3β, CXCR4 and MMP2 expression in a
D; *p < 0.05 compared to control cells
Ying et al. Cancer Cell International  (2015) 15:70 Page 3 of 8CXCR4 and MMP-2 expression by about 2.4- and
2.1-fold, respectively, compared to control PANC1
cells and vector control cells (Fig. 1b and Additional
file 1: Figure S2A). And the same phenomenon was
aslo observed in SW-1990 cells (Fig. 1c and d).
Inhibition of GSK3β downregulates CXCR4 and MMP-2
expression
Furthermore, we assesse whether inhibition of GSK3β af-
fected CXCR4 and MMP-2 expression in PANC1 and
SW-1990 cells. Using two different types of RNA interfer-
ence, GSK3β expression is successfully down-regulated
(Fig. 2a and b). Scrambled shRNA is used as a control.
Suppression of GSK3β expression significantly reduces
CXCR4 and MMP-2 expression approximately 2.3 folds
and 5.8 folds in PANC1 cells, compared to scrambled con-
trol cells (Fig. 2a, b and Additional file 1: Figure S2B). And
the same phenomenon was aslo observed in SW-1990
cells (Fig. 2c and d). We also detected the effect of GSK3β
inhibition on the expression of CXCR4 and activity of
downstream signaling molecular β-catenin using GSK3-Fig. 2 Inhibition of GSK3β downregulates CXCR4 and MMP2 expressio
transfected with the GSK3β silencing plasmid pcDNA6.2-GW/EmGFP-m
and stable cell clones were selected. Total cell lysates were isolated a
CXCR4 and MMP-2 antibodies; α-tubulin was used as a loading contr
(C) GSK3β, CXCR4 and MMP-2 protein expression in SW-1990 cells. b
a and c based on gray-scale analysis. Results are expressed as the mspecific inhibitor AR-A014418. Additional file 2: Figure S1
showed that inhibition of GSK3β downregulated CXCR4
expression and suppressed phosphorylation of β-catenin.
GSK3β promotes PANC1 cell invasion
We examine the effect of GSK3β on cell invasion in
PANC1 cells using the in vitro cell invasion assay. As
shown in Fig. 3a and b, the cell invasion assay demon-
strates that overexpression of GSK3β promoted the inva-
sion of PANC1 cells compared to vector control cells;
suppression of GSK3β decreases the invasion of PANC1
cells compared to the scrambled cells. These results in-
dicate that GSK3β induces PANC1 cell invasion.
PANC1 cell invasion induced by overexpression of GSK3β
is attenuated by suppression of CXCR4
MMP-2 degrades the extracellular matrix, which pro-
motes cancer cell invasion, and we previousl [21] found
that CXCR4 promoted human cancer cell invasion by up-
regulating MMP-2. In this study, we observe that GSK3β
regulated CXCR4 and MMP-2 expression (Figs. 1 and 2).n. PANC1 and SW-1990 human pancreatic cancer cells were
iR-GSK3β expression vector, or scrambled vector as a control,
nd subjected to Western blotting using anti-human GSK3β,
ol. a GSK3β, CXCR4 and MMP-2 protein expression in PANC1 cells.
and d Quantification of GSK3β, CXCR4 and MMP-2 expression in
ean ± SD; *p < 0.05 compared to control cells
Fig. 3 GSK3β promotes PANC1 human pancreatic cancer cells invasion. Transwell invasion assay was employed to determine the effect of GSK3β
on cell invasion. Stable cell clones of PANC1 cells overexpression or suppression of GSK3β were selected. 200 μl cell suspension maitained in
serum-free DMEM/0.1 % BSA were added to the matrigel-coated upper compartment, the DMED/10%FBS medium was added to the lower
compartment, and the plates were incubated for 48 h at 37 °C. a After incubation for 48 h, the upper surface of the filter was scrubbed free of
cells, the filter was fixed and stained and the lower surface was photographed (200× original magnification). b Quantification of A. Results are
expressed as the mean ± SD; *p < 0.05 compared to control cells
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MMP-2 expression and cell invasion via CXCR4 sig-
naling. To determine the effect of CXCR4 on cell in-
vasion induced by GSK3β overexpression, PANC1
cells overexpression GSK3β were transfected with the
CXCR4 silencing plasmids, or scrambled vector as a
control, and stable cell clones were selected. Western
blotting result showes that CXCR4 protein is success-
fully suppressed (Fig. 4a and b).
As shown in Fig. 4a and b, up-regulation of MMP-2
induced by overexpression of GSK3β is attenuated by
the CXCR4 inhibition using transfecting with CXCR4
shRNA plasmids. Fig. 4c shows that overexpression of
GSK3β also increased the invasion of PANC1 cells com-
pared to the control cells. However, the ability of GSK3β
to promote cell invasion is reduced by the CXCR4 inhib-
ition. These results indicate that GSK3β induces MMP-2expression and cell invasion via a CXCR4-dependent
mechanism in PANC1 cells.
Discussion
Among the current range of novel target molecules,
GSK3β has emerged as a therapeutic target in pancreatic
cancer [8, 22, 23]. GSK3β expression and activity are up-
regulated in pancreatic cancer [24–28]. In spite of this
evidence, the precise role of GSK3β and its potential as
a therapeutic target in pancreatic cancer still require fur-
ther research. The focus of this study was to determine
the effects of GSK3β and investigate its molecular mech-
anism of action, specifically via the GSK3β-CXCR4/
MMP-2 pathway, in PANC1 pancreatic cancer cells.
Previous studies have shown that inhibition of GSK3β
reduced the proliferation and survival of pancreatic can-
cer cells, which was associated with decreased cyclin D1
Fig. 4 Overexpression of GSK3β promotes PANC1 cell invasion and MMP-2 expression via a CXCR4-dependent mechanism. To determine
the effect of CXCR4 on cell invasion induced by GSK3β overexpression, PANC1 cells overexpression GSK3β were transfected with the
CXCR4 silencing plasmids, or scrambled vector as a control, and stable cell clones were selected. a Total cell lysates were isolated and
subjected to Western blotting using anti-MMP-2 and anti-CXCR4-antibodies; α-tubulin was used as a loading control. b Quantification of
CXCR4 and MMP-2 expression in a based on gray-scale analysis. c Transwell invasion assay was employed to determine the effect of
CXCR4 on PANC1 cells invasion induced by GSK3β overexpression. d Quantification of A. Results are expressed as the mean ± SD;
*p < 0.05 compared to control cells
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metalloproteinase-2 (MMP-2) [26, 29, 30]. Inhibition of
GSK3β also suppressed pancreatic cancer growth and
angiogenesis by decreasing the expression of Blc-2 and
vascular endothelial growth factor (VEGF), and abrogat-
ing NFκB activity [17, 31]. GSK3β also maintained
constitutive NFκB signaling in pancreatic cancer cells
[9, 32–34]. The GSK3β/β-catenin pathway has also
been linked to pancreatic cancer [35]. These results
led us to propose GSK3β as a potential therapeutic
target in pancreatic cancer; therefore, further studies
on the molecular mechanism of action of GSK3β are
required. The effect of GSK3β on SDF-1/CXCR4 is
complicated. Kim YS et al. sugguested that inhibitionof GSK3β upregulated expression of CXCR4 but Tamura
M et al. said that silencing of GSK3β decreased SDF-1 ex-
pression [18, 20]. SDF-1 might increase GSK3β phosphor-
ylation [19]. SDF-1/CXCR4 aslo mediated GSK3β-induced
physiological migration of stem cells [36]. Activation of
CXCR4-mediated cell signal resulted in the inhibition of
GSK3β [37].
In our previous study [21], we found that SDF-1α/
CXCR4 upregulated MMP-2 expression and induced the
invasion of PANC1 and SW-1990 pancreatic cancer cells
by activating p38 MAPK. Additionally, inhibition of
GSK3β reduced the secretion of MMP-2 [26]. These re-
sults shed light on the molecular mechanism of action
of GSK3β in pancreatic cancer. In this study, we
Ying et al. Cancer Cell International  (2015) 15:70 Page 6 of 8demonstrated that GSK3β induced PANC1 pancreatic
cancer cell invasion via the CXCR4/MMP-2 pathway.
Conclusions
This study provides further insight into the molecular
mechanism of GSK3β-induced pancreatic cancer inva-
sion, and will allow exploration of novel therapeutic




Dulbecco’s modified Eagle’s medium (DMEM; #11965-
084) was purchased from Life TechnologiesTM (USA). The
α-Tubulin antibody (#T5168) and AR-A014418 (#487021-
52-3, an inhibitor of GSK3) were purchased from Sigma-
Aldrich (USA). Antibodies against GSK3β (#9315) and
MMP-2 (#4022) were purchased from Cell Signaling
Technology (USA). Antibodies against CXCR4 (#ab2074)
was purchased from Abcam.
Cell culture
The human pancreatic cancer cell line PANC1 (CRL-
1469) and SW-1990 (CRL-2172), which was established
from human pancreatic cancer ducts, was purchased from
the American Type Culture Collection (ATCC, Manassas,
VA, USA). PANC1 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10 % fetal bovine serum, 100 U/ml penicillin and 100 mg/
ml streptomycin sulfate, and maintained at 37 °C in a 5 %
CO2 humidified incubator.
Construction of GSK3β overexpressing plasmid and
generation of stable clones
The overexpressing plasmid pcDNA3.1A(-)-myc-GSK3β
was constructed as follows: full-length human GSK3β
cDNA was amplified by RT-PCR from mRNA isolated
from human white adipose tissue. The primer sequences
were: forward, 5'-CGTGAATTCATCATGTCAGGGCG
GCCCA -3' and reverse, 5'-GCTGTCGACG GGATCCG
TCAGGTGGAGTTGGA-3'. The PCR product was
cloned into the expression vector pcDNA3.1A(-)-myc,
and then transfected into PANC1 cells using X-
tremeGENE HP DNA Transfection Reagent. At 48 hTable 1 Reverse complementary oligonucleotides






Scrambled-R TACTAAAGTCAAafter transfection, the cells were cultured in selection
medium containing 800 μg/ml G418 (Sigma) to select
resistant colonies for further analysis.
Construction of miRNA-GSK3β expression plasmids and
stable clone selection
Two distinct domains within the coding region of the
human GSK3β cDNA were targeted for RNA interfer-
ence. For this purpose, two pairs of reverse complemen-
tary oligonucleotides were designed and synthesized as
Table 1. The oligonucleotides were annealed and
inserted into the pcDNA6.2-GW/EmGFP-miR expres-
sion vector (Invitrogen, #K4936-00) to create GSK3β
shRNA1 and shRNA2. A control scrambled shRNA was
also created. We used X-tremeGENE HP DNA Trans-
fection Reagent to separately transfect the three kinds
of plasmids into PANC-1. At 48 h after transfection, the
cells were cultured in selection medium containing
800 μg/ml G418 (Sigma) to select resistant colonies for
further analysis. CXCR4 shRNA plasmids are gifts from
the Department of Gastroenterology, The First Affili-
ated Hospital of Nanjing Medical University [38].
Western blotting analysis
PANC1 cells were lysed using RIPA buffer. Equal amounts
of protein (60 μg) were separated on 10 % SDS-PAGE gels
and transferred to Immobilon-P membranes (Millipore,
Bedford, MA, USA). The membranes were probed over-
night at 4 °C with antibodies against GSK3β, CXCR4 or
MMP-2 in TBST containing 1 % (w/v) BSA, incubated with
the appropriate anti-rabbit or anti-mouse secondary anti-
bodies for 2 h, and immune complexes were detected using
the ECL plus detection kit (Pierce, Rockford, IL, USA) and
quantified using a scanning densitometer and molecular
analysis software (Bio-Rad, Hercules, CA, USA).
Cell invasion assay
PANC1 cell invasion was assayed using 24-well Trans-
well plates (Corning Costar, Schiphol-Rijk, Netherlands).
ECM gel solution (60 μl) was added to the top compart-
ment of each cell culture insert and dried overnight in a
laminar flow cabinet. PANC1 cells were washed twice with
phosphate-buffered saline (PBS), resuspended in serum-






Ying et al. Cancer Cell International  (2015) 15:70 Page 7 of 8concentration of 1 × 106 cells/ml. Serum-free DMEM/
0.1 % BSA (600 μl) and 200 μl cell suspension were added
to the matrigel-coated upper compartment, and the same
medium was added to the lower compartment, and the
plates were incubated for 48 h at 37 °C. Cells remaining
on the upper side of the filter were removed by gentle
wiping, and cells that had migrated through the filter were
counted using a light microscope (six fields were counted
in each chamber for each condition; 200× magnification).
Statistical analysis
Data were analyzed by two-tailed Student t test for
single comparisons and by one-way analysis of vari-
ance for multiple group comparisons. Differences
were considered significant at *p < 0.05 versus control.
Additional files
Additional file 1: Figure S2. The transcript levels for CXCR4 and MMP2
were quantified by real-time quantitative transcription polymerase chain
reaction (real-time PCR). Total RNA of PANC-1 cells were extracted by
TRIzol reagent (Invitrogen) and 1 μg total RNA was used for reverse
transcription to cDNA according to the manufacturer’s instructions. The
cDNA aliquots were used for quantification of mRNA by real-time PCR
using ABI Prism 7000 sequence detection system (Applied Biosystems,
Foster City, CA), using SYBR Green PCR master mix (Applied Biosystems). All
data were analyzed using β-actin gene expression as an internal standard.
The specific primers were as follows: β-actin forward: 5′-TCACCAA
CTGGGACGACAT-3′, and reverse: 5′-GCACAGCCTGGATAGCAAC-3′,
CXCR4 (NM_001008540.1) forward: 5′-CGAGGCCCTAGCTTTCTTCC-3′,
and reverse: 5′-GAGGATCTTGAGGCT GGACC-3′, MMP2
(NM_001302509.1) forward: 5′-GGATGGCAAGTACGGCTTCT-3′, and
reverse: 5′-GTT CCCACCAACAGTGGACA-3′. The thermal cycler was
programmed as: denaturation at 95 °C for 5 min, followed by 33
cycles at 95 °C for 30 s and annealing at 60 °C for β-actin, 60 °C for
CXCR4, and 56 °C for MMP2 for 30 s, extension in all was carried at 72 °C for
1 min, with a final extension step of 10 min. (A) Overexpression of GSK3β
upregulates CXCR4 and MMP-2 expression respectively, compared to control
PANC1 cells and vector control cells. (B) Suppression of GSK3β expression
significantly reduces CXCR4 and MMP-2 expression approximately 2.3 folds
and 5.8 folds in PANC1 cells, compared to scrambled control cells.
Additional file 2: Figure S1. Effect of GSK3 inhibition on
phosporylation of β-catenin and CXCR4 expression. The levels of
phosphorylation of β-catenin and CXCR4 expression were examined
by Western blotting in pancreatic cancer cells PANC-1 after treatment
with 10 μM AR-A014418 (AR) (#487021-52-3, an inhibitor of GSK3,
was purchased from Sigma-Aldrich (USA)) for 6 hous. Expression of
CXCR4 and β-catenin and its phosphorylation (p-β-catenin S33/37/
T41) (Phospho-β-catenin (Ser33/37/Thr41) #9561 antibody and
β-catenin antibody #9562 were purchased from CST) were examined
and compared between the same pancreatic cancer cells treated
with DMSO or AR-A014418.
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